The effectiveness and safety of mycophenolate mofetil in lupus nephritis

Mazen Elyan, Stanley Ballou

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The purpose of this study is to evaluate the effectiveness and safety of mycophenolate mofetil (MMF) for inducing and/or maintaining remission of lupus nephritis (LN). This is a retrospective study of 25 LN patients consecutively treated with MMF. The primary outcome was complete renal remission (CR) defined by urine protein/creatinine ratio ≤0.5 g/g and inactive urine sediment and serum creatinine within <15% above baseline. For induction, 21 episodes of active, moderate to severe LN were treated with MMF. Twelve cases (57%) achieved CR over a median of 8.5 months. Of 13 patients who had LN for <12 months and took ≥2 g/ day of MMF, 11 achieved CR, compared to one out of the eight patients who did not meet both criteria (p = 0.0022). For maintenance therapy, 15 patients received MMF for a median of 20 months (range 5-55 months). Two patients (13%) experienced renal flares while taking MMF. Most adverse events were transient and did not require change in therapy. This study suggests that MMF is an effective treatment for both induction and maintenance of remission of moderate to severe LN with a relatively favorable safety profile. Early treatment and a dose ≥2 g/day are essential for optimal outcome. CR may take >6 months.

Original languageEnglish (US)
Pages (from-to)835-840
Number of pages6
JournalClinical Rheumatology
Volume28
Issue number7
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Mycophenolic Acid
Lupus Nephritis
Creatinine
Urine
Safety
Retrospective Studies
Kidney
Serum
Proteins

Keywords

  • Lupus
  • Lupus nephritis
  • Mycophenolate
  • Mycophenolate mofetil
  • Renal lupus
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology

Cite this

The effectiveness and safety of mycophenolate mofetil in lupus nephritis. / Elyan, Mazen; Ballou, Stanley.

In: Clinical Rheumatology, Vol. 28, No. 7, 2009, p. 835-840.

Research output: Contribution to journalArticle

Elyan, Mazen ; Ballou, Stanley. / The effectiveness and safety of mycophenolate mofetil in lupus nephritis. In: Clinical Rheumatology. 2009 ; Vol. 28, No. 7. pp. 835-840.
@article{3a615c97fd144d0da9bcbee508d6fad9,
title = "The effectiveness and safety of mycophenolate mofetil in lupus nephritis",
abstract = "The purpose of this study is to evaluate the effectiveness and safety of mycophenolate mofetil (MMF) for inducing and/or maintaining remission of lupus nephritis (LN). This is a retrospective study of 25 LN patients consecutively treated with MMF. The primary outcome was complete renal remission (CR) defined by urine protein/creatinine ratio ≤0.5 g/g and inactive urine sediment and serum creatinine within <15{\%} above baseline. For induction, 21 episodes of active, moderate to severe LN were treated with MMF. Twelve cases (57{\%}) achieved CR over a median of 8.5 months. Of 13 patients who had LN for <12 months and took ≥2 g/ day of MMF, 11 achieved CR, compared to one out of the eight patients who did not meet both criteria (p = 0.0022). For maintenance therapy, 15 patients received MMF for a median of 20 months (range 5-55 months). Two patients (13{\%}) experienced renal flares while taking MMF. Most adverse events were transient and did not require change in therapy. This study suggests that MMF is an effective treatment for both induction and maintenance of remission of moderate to severe LN with a relatively favorable safety profile. Early treatment and a dose ≥2 g/day are essential for optimal outcome. CR may take >6 months.",
keywords = "Lupus, Lupus nephritis, Mycophenolate, Mycophenolate mofetil, Renal lupus, Systemic lupus erythematosus",
author = "Mazen Elyan and Stanley Ballou",
year = "2009",
doi = "10.1007/s10067-009-1163-6",
language = "English (US)",
volume = "28",
pages = "835--840",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",
number = "7",

}

TY - JOUR

T1 - The effectiveness and safety of mycophenolate mofetil in lupus nephritis

AU - Elyan, Mazen

AU - Ballou, Stanley

PY - 2009

Y1 - 2009

N2 - The purpose of this study is to evaluate the effectiveness and safety of mycophenolate mofetil (MMF) for inducing and/or maintaining remission of lupus nephritis (LN). This is a retrospective study of 25 LN patients consecutively treated with MMF. The primary outcome was complete renal remission (CR) defined by urine protein/creatinine ratio ≤0.5 g/g and inactive urine sediment and serum creatinine within <15% above baseline. For induction, 21 episodes of active, moderate to severe LN were treated with MMF. Twelve cases (57%) achieved CR over a median of 8.5 months. Of 13 patients who had LN for <12 months and took ≥2 g/ day of MMF, 11 achieved CR, compared to one out of the eight patients who did not meet both criteria (p = 0.0022). For maintenance therapy, 15 patients received MMF for a median of 20 months (range 5-55 months). Two patients (13%) experienced renal flares while taking MMF. Most adverse events were transient and did not require change in therapy. This study suggests that MMF is an effective treatment for both induction and maintenance of remission of moderate to severe LN with a relatively favorable safety profile. Early treatment and a dose ≥2 g/day are essential for optimal outcome. CR may take >6 months.

AB - The purpose of this study is to evaluate the effectiveness and safety of mycophenolate mofetil (MMF) for inducing and/or maintaining remission of lupus nephritis (LN). This is a retrospective study of 25 LN patients consecutively treated with MMF. The primary outcome was complete renal remission (CR) defined by urine protein/creatinine ratio ≤0.5 g/g and inactive urine sediment and serum creatinine within <15% above baseline. For induction, 21 episodes of active, moderate to severe LN were treated with MMF. Twelve cases (57%) achieved CR over a median of 8.5 months. Of 13 patients who had LN for <12 months and took ≥2 g/ day of MMF, 11 achieved CR, compared to one out of the eight patients who did not meet both criteria (p = 0.0022). For maintenance therapy, 15 patients received MMF for a median of 20 months (range 5-55 months). Two patients (13%) experienced renal flares while taking MMF. Most adverse events were transient and did not require change in therapy. This study suggests that MMF is an effective treatment for both induction and maintenance of remission of moderate to severe LN with a relatively favorable safety profile. Early treatment and a dose ≥2 g/day are essential for optimal outcome. CR may take >6 months.

KW - Lupus

KW - Lupus nephritis

KW - Mycophenolate

KW - Mycophenolate mofetil

KW - Renal lupus

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=67349222206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349222206&partnerID=8YFLogxK

U2 - 10.1007/s10067-009-1163-6

DO - 10.1007/s10067-009-1163-6

M3 - Article

C2 - 19319623

AN - SCOPUS:67349222206

VL - 28

SP - 835

EP - 840

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 7

ER -